[Skip to Content]
[Skip to Content Landing]
Views 325
Citations 0
Editorial
October 2018

Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance

Author Affiliations
  • 1Department of Dermatology, University of Connecticut Health Center, Farmington
  • 2Probity Medical Research, Waterloo, Ontario, Canada
  • 3Medical College of Wisconsin, Milwaukee
JAMA Dermatol. 2018;154(10):1135. doi:10.1001/jamadermatol.2018.1166

Standardized and relevant psoriasis-specific outcome measures would contribute to a better understanding of the benefits of a growing list of highly effective therapies. To this end, in this issue of JAMA Dermatology, Callis Duffin et al1 present the results of an effort to define core outcome sets (COSs) for clinical trials of psoriasis. Under the auspices of the International Dermatology Outcome Measures group, the authors conducted a Delphi survey and determined that the following 6 domains should be addressed in all psoriasis trials: (1) psoriatic skin manifestations (including location), (2) an investigator global assessment, (3) an evaluation of signs and symptoms of both psoriasis and psoriatic arthritis, (4) a patient global assessment of his or her condition, (5) an assessment of treatment satisfaction, and (6) a measure of health-related quality of life.

×